Our overall mission is to make visible impact on prognosis of brain cancer patients by developing novel and innovative therapies. Brain cancers are highly aggressive, invasive, and resistant to current therapies. Therefore, the vast majority of patients with malignant tumors elude effective treatment resulting in subsequent lethality. We, as a team, continue to devote ourselves towards improving the outcomes of patients by developing effective therapies for this devastating disease in collaboration with our collaborators in broad areas including basic scientists, oncologists, pathologists, and surgeons.

Recent News
November 2017
Dr. Daisuke Yamashita joined our team as a Post Doctoral Scholar. Dr. Yamashita joins us from Brigham and Women’s Hospital/Harvard Medical School and was previously an Assistant Professor at Ehime University Graduate School of Medicine in Japan. 
Aug  2017
Mr. Kai Takamatsu, Mr. Shun Fujimori, Mr. Hiroyuki Kanazawa, three medical students from Shiga University of Medical Science, in Shiga, Japan, visited our lab for two weeks.
Jun 2017
Dr. Jia Wang and his team published a research article titled “Targeting NEK2 attenuates glioblastoma growth and radio-resistance by destabilizing EZH2” in JCI.
Apr 2017
Our new administrative assistant, Jennifer Lancaster joined our team!
Mar 2017
Drs. Minata and Alsheikh, Ms. Yamaguchi and our graduate student, Ms. Bastola attended the Annual Meeting for the AACR (American Association for Cancer Research). Ms. Bastola was awarded a travel award to attend. 
Dr. Kyung-Don Kang joined our team!
Feb 2017
Dr. Suojun Zhang joined our team as a Visiting Scientist. Dr. Zhang is a neurosurgeon in China.
Jan 2017
We received additional grant support from the Breast Cancer Research Foundation in Alabama!
Jan 2017
Mr. Shinji Kawamura joined our team!
Jan 2017
We published 17 research articles/reviews including those in Cancer Cell, Cancer Res, JCI, Nat Comm, and others in 2016.
Oct 2016
Dr. Cheng and his team in the Nakano lab published a research article about ALDH1 in glioblastoma in Cancer Research.
Another NIH/R01 with Dr. Nakano as co-Investigator got 7 percentile. If funded, this is the 8rd NIH grant with Dr. Nakano as either PI or co-I.
Aug 2016
Dr. Kim received a faculty position in Chounam National University.